首页> 外国专利> DYNAMIC OF SFLT-1 OR ENDOGLiN/PIGF RATIO AS AN INDICATOR FOR IMMINENT PREECLAMPSIA AND/OR HELLP SYNDROME

DYNAMIC OF SFLT-1 OR ENDOGLiN/PIGF RATIO AS AN INDICATOR FOR IMMINENT PREECLAMPSIA AND/OR HELLP SYNDROME

机译:SFLT-1或内皮素/促生长因子比值作为即将发生的子痫前期和/或HELLP综合征指标的动态变化

摘要

Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.
机译:诊断方法和工具,用于诊断怀孕受试者是否在短时间内有患先兆子痫和/或早发先兆子痫的风险。所述方法包括测定所述受试者的第一和第二样本中的生物标记物sFlt-1或内皮素和PIGF的量,所述第一样本在所述第二样本之前获得;根据在第一个样品中测定的sFlt-1或内皮素和PIGF的量计算第一比率,并根据在第二个样品中测定的sFlt-1或内皮素和PIGF的量计算第二比率;以及比较第一和第二比率的值,其中,如果第二比率的值比第一比率的值增加至少约3倍,则诊断在短时间内有患先兆子痫风险的受试者。

著录项

  • 公开/公告号US2022128568A1

    专利类型

  • 公开/公告日2022-04-28

    原文格式PDF

  • 申请/专利权人 ROCHE DIAGNOSTICS OPERATIONS INC.;

    申请/专利号US202117463876

  • 发明设计人 BARBARA DENK;MARTIN HUND;

    申请日2021-09-01

  • 分类号G01N33/68;C07K16/22;G01N33/74;

  • 国家 US

  • 入库时间 2022-08-25 00:46:13

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号